Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes.
Keith BoweringJ HarveyJ W KolaczynskiJ W SnyderB W BodePublished in: Diabetic medicine : a journal of the British Diabetic Association (2018)
Fast-acting insulin aspart may hold promise as a more effective treatment compared with insulin aspart for controlling PPG in people with insulin-resistant Type 2 diabetes.